id_covidence,doi,pmid,pmcid,link,study,published_year,journal,title
#9763,10.23736/s2724-606x.22.05148-x,36193832,,,Safrai 2024,2024,Minerva Obstet Gynecol,BNT162b2 COVID-19 vaccine does not affect fertility as explored in a pilot study of women undergoing IVF treatment
#4579,10.1080/21645515.2023.2190279,36919537,PMC10072113,,Amicizia 2023,2023,Hum Vaccin Immunother,Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
#7509,10.1212/CPJ.0000000000200166,37251368,PMC10212233,,Kim 2023,2023,Neurology: Clinical Practice,"Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021"
#5965,10.1016/j.lanepe.2023.100628,37261212,PMC10091277,,Dulfer 2023,2023,The Lancet Regional Health - Europe,"Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial"
#8961,10.1007/s00246-023-03200-2,37294336,PMC10251331,,Nv 2024,2024,Pediatr Cardiol,Longitudinal Assessment of Left Ventricular Function in Patients with Myopericarditis After mRNA COVID-19 Vaccination
#12347,10.1097/wno.0000000000001900,37314860,,,Jaffry 2023,2023,J Neuroophthalmol,Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System
#10548,10.1080/09273948.2023.2220782,37315304,,,Testi 2024,2024,Ocul Immunol Inflamm,Ocular Inflammatory Events Following COVID-19 Vaccination in the Paediatric Population: A Multinational Case Series
#8848,10.1016/j.jiac.2023.07.008,37481070,,,Nakashima 2023,2023,J Infect Chemother,Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study
#9547,10.1097/aog.0000000000005279,37535959,,,Regan 2023,2023,Obstet Gynecol,Risk of Miscarriage in Relation to Seasonal Influenza Vaccination Before or During Pregnancy
#8735,10.1016/j.vaccine.2023.07.043,37544827,,,Moscara 2023,2023,Vaccine,Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study
#8678,10.1093/cid/ciad477,37584344,PMC10810716,,Mombelli 2024,2024,Clin Infect Dis,Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)
#10041,10.1186/s12979-023-00367-3,37644610,PMC10463383,,Shapiro 2023,2023,Immunity and Ageing,The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults
#12280,10.1001/jamaneurol.2023.2968,37669073,PMC10481324,,Grimaldi 2023,2023,JAMA Neurol,Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups
#6513,10.1001/jamanetworkopen.2023.32813,37682571,PMC10492184,,Gonen 2023,2023,JAMA Netw Open,Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
#8796,10.1007/s40121-023-00863-5,37698774,PMC10581992,,Murdoch 2023,2023,Infectious Diseases and Therapy,Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
#12733,10.1186/s12916-023-03064-6,37726711,PMC10510262,,Werner 2023,2023,BMC Med,Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study
#7899,10.1093/ibd/izad198,37773982,PMC11291623,,Lee 2024,2024,Inflamm Bowel Dis,Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
#8201,10.1186/s12889-023-16768-4,37784088,PMC10546661,,Lophatananon 2023,2023,BMC Public Health,The association of herpes zoster and influenza vaccinations with the risk of developing dementia: a population-based cohort study within the UK Clinical Practice Research Datalink
#7846,10.1212/wnl.0000000000207847,37788935,,,LeVu 2023,2023,Neurology,Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study
#10236,10.1007/s40264-023-01356-7,37882905,,,Slingerland 2023,2023,Drug Saf,"The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands"
#9345,10.3390/vaccines11101528,37896932,PMC10611124,,Poder 2023,2023,Vaccines,"Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age"
#10102,10.3390/vaccines11101586,37896989,PMC10611167,,Shi 2023,2023,Vaccines,Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
#8739,10.3390/vaccines11101624,37897026,PMC10610948,,Moss 2023,2023,Vaccines,Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
#9507,10.1016/j.vaccine.2023.10.050,37903680,,,Ramsay 2023,2023,Vaccine,"A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study)"
#10011,10.1177/19417381231208677,37946492,PMC11195857,,Shah 2024,2024,Sports Health,Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes
#4716,10.1093/cid/ciad707,37992000,PMC11093669,,Athan 2024,2024,Clin Infect Dis,Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults
#10549,10.1136/bjo-2023-324503,38041661,,,Testi 2024,2024,Br J Ophthalmol,Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK
#9379,10.1016/j.vaccine.2023.11.050,38042698,PMC10733862,,Prasert 2024,2024,Vaccine,"Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial"
#6336,10.1055/a-2183-5269,38053618,PMC10695705,,Gaddh 2023,2023,TH Open,Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
#4742,10.1080/22221751.2023.2292068,38054302,PMC10798284,,Aydillo 2024,2024,Emerg Microbes Infect,Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines
#16349,10.1111/all.15968,38071735,,,Lee 2024,2024,Allergy,"Global burden of vaccine-associated anaphylaxis and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
#7881,10.1136/bmjresp-2023-001992,38081769,PMC10729117,,Lee 2023,2023,BMJ Open Respir Res,Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)
#6771,10.1080/09286586.2023.2289990,38085757,,,Hashimoto 2024,2024,Ophthalmic Epidemiol,Ocular Adverse Events After Influenza Vaccination in Older Adults: Self-Controlled Case Series Using a Large Database in Japan
#10479,10.1111/ene.16172,38117538,PMC11236019,,Tanaka 2024,2024,Eur J Neurol,"Risk of stroke within 3, 7, 14, 21 and 30 days after influenza vaccination in Alberta, Canada: A population-based study"
#11049,10.1093/infdis/jiad594,38134393,PMC11326816,,Widagdo 2024,2024,J Infect Dis,Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial
#6252,10.1016/j.vaccine.2023.12.074,38154990,,,Fonseca 2024,2024,Vaccine,In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial
#7501,10.1080/25785826.2023.2300163,38189429,,,Kikuchi 2024,2024,Immunol Med,Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus
#13821,10.1093/cid/ciad786,38189778,,,Chandler 2024,2024,Clin Infect Dis,"Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial"
#10254,10.2807/1560-7917.Es.2024.29.2.2300709,38214082,,,Smolarchuk 2024,2024,Euro Surveill,"Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
#4368,10.1016/j.ophtha.2024.01.020,38242364,,,Aftab 2024,2024,Ophthalmology,Ophthalmologic Complications in Coronavirus Disease 2019 Immunization: A National Vaccine Adverse Event Reporting System Analysis
#5483,10.1016/j.cmi.2024.01.010,38253313,,,Choi 2024,2024,Clin Microbiol Infect,Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference
#9686,10.1080/07853890.2023.2295979,38289017,PMC10829820,,Rossier 2024,2024,Ann Med,SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study
#10057,10.1093/infdis/jiae035,38298125,PMC11420805,,Shaw 2024,2024,J Infect Dis,"Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial"
#6253,10.14309/ajg.0000000000002702,38314748,PMC11296936,,Fontana 2024,2024,Am J Gastroenterol,ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study
#6597,10.1016/j.vaccine.2024.01.023,38341288,,,Grima 2024,2024,Vaccine,The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data
#5332,10.1093/infdis/jiae067,38349280,PMC11326827,,Chalkias 2024,2024,J Infect Dis,Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines
#8294,10.1097/hep.0000000000000787,38358465,,,Maan 2024,2024,Hepatology,Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination: A Vascular Liver Disease Group (VALDIG) initiative
#10228,10.2807/1560-7917.Es.2024.29.7.2400076,38362622,,,Skowronski 2024,2024,Euro Surveill,2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
#10056,10.1093/infdis/jiae081,38385566,PMC11420773,,Shaw 2024,2024,J Infect Dis,Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults
#8492,10.2807/1560-7917.Es.2024.29.8.2400089,38390651,,,Maurel 2024,2024,Euro Surveill,"Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
#8718,10.1007/s40264-024-01406-8,38411838,PMC11646557,,Moro 2024,2024,Drug Saf,Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)
#14416,10.2196/45536,38412008,PMC10933718,,Dreyer 2024,2024,JMIR Diabetes,COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters
#6300,10.15585/mmwr.mm7308a3,38421935,PMC10907036,,Frutos 2024,2024,MMWR Morb Mortal Wkly Rep,Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States
#11574,10.15585/mmwr.mm7308a4,38421946,PMC10907038,,Zhu 2024,2024,MMWR Morb Mortal Wkly Rep,"Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024"
#10824,10.1080/21645515.2024.2323853,38445666,PMC10936640,,Villanueva 2024,2024,Hum Vaccin Immunother,Factors influencing adverse events following COVID-19 vaccination
#8305,10.1080/21645515.2024.2322196,38448394,PMC10936612,,Machado 2024,2024,Hum Vaccin Immunother,Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season
#7465,10.1016/j.jaci.2024.03.001,38460680,PMC11162316,,Khalid 2024,2024,J Allergy Clin Immunol,A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
#4362,10.1097/mnm.0000000000001833,38465449,,,Adin 2024,2024,Nucl Med Commun,Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines
#10138,10.1093/cid/ciae132,38465901,,,Shrestha 2024,2024,Clin Infect Dis,Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine
#10466,10.1016/j.jocmr.2024.101036,38479457,PMC11004989,,Talib 2024,2024,J Cardiovasc Magn Reson,Cardiovascular magnetic resonance imaging and clinical follow-up in patients with clinically suspected myocarditis after COVID-19 vaccination
#5917,10.1007/s40264-024-01395-8,38483767,PMC10955014,,DosSantos 2024,2024,Drug Saf,"An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older"
#8240,10.1001/jama.2024.1059,38502075,PMC10951737,,Lu 2024,2024,Jama,Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults
#6209,10.1093/infdis/jiae140,38513368,PMC11420796,,Figueroa 2024,2024,J Infect Dis,Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients
#8828,10.1080/21645515.2024.2327736,38513689,PMC10962584,,Naficy 2024,2024,Hum Vaccin Immunother,No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
#5870,10.1016/s1473-3099(24)00101-4,38518789,,,Dixit 2024,2024,Lancet Infect Dis,Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
#7517,10.1016/j.jaci.2024.01.025,38520423,,,Kim 2024,2024,J Allergy Clin Immunol,"Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea"
#4993,10.1016/j.vaccine.2024.03.060,38531725,,,Biegus 2024,2024,Vaccine,The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure
#4877,10.1089/derm.2023.0379,38535725,,,Battis 2024,2024,Dermatitis,Patient-Reported Association Between COVID-19 Infection or Vaccination and Onset of Allergic Contact Dermatitis®
#5595,10.3390/vaccines12030305,38543939,PMC10976042,,Costantino 2024,2024,Vaccines,Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System
#8011,10.3390/vaccines12030321,38543956,PMC10975893,,Li 2024,2024,Vaccines,Exploratory Study of the Phase IV Immunization Schedule of Quadrivalent Influenza Split-Virion Vaccine in Children Aged 3–8 Years
#8103,10.15585/mmwr.mm7312a5,38547037,PMC10986819,,Link-Gelles 2024,2024,MMWR Morb Mortal Wkly Rep,"Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024"
#7164,10.1080/21645515.2024.2334084,38563792,PMC10989707,,Jarrot 2024,2024,Hum Vaccin Immunother,Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
#4849,10.1093/ofid/ofae144,38567194,PMC10986856,,Barouch 2024,2024,Open Forum Infectious Diseases,Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses
#10421,10.1001/jamanetworkopen.2024.4954,38573635,PMC11192181,,Surie 2024,2024,JAMA Netw Open,Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
#9213,10.1016/j.ebiom.2024.105103,38574407,PMC11004685,,Pattinson 2024,2024,EBioMedicine,Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses
#4880,10.1016/j.vaccine.2024.03.061,38580516,,,Baum 2024,2024,Vaccine,Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial
#4765,10.1111/1346-8138.17188,38605482,,,Baba 2024,2024,J Dermatol,Cutaneous adverse events following COVID-19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies
#10878,10.1093/infdis/jiae185,38606958,PMC11481295,,Walsh 2024,2024,J Infect Dis,Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination
#4695,10.1007/s13760-024-02536-7,38619748,,,A_kınTuran 2024,2024,Acta Neurol Belg,A retrospective cohort study: is COVID-19 BNT162b2 mRNA vaccination a trigger factor for cluster headache?
#11097,10.1016/j.vaccine.2024.03.078,38641496,,,Won 2024,2024,Vaccine,Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
#5489,10.3346/jkms.2024.39.e146,38651226,PMC11035711,,Choi 2024,2024,J Korean Med Sci,Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
#14940,10.14745/ccdr.v50i12a02,38655243,PMC11037881,,Giang 2024,2024,Can Commun Dis Rep,"Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022"
#7521,10.1001/jamaophthalmol.2024.0973,38662361,PMC11046406,,Kim 2024,2024,JAMA Ophthalmol,COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis
#2222,10.1080/14740338.2024.2348568,38666296,,,Liu 2025,2025,Expert Opin Drug Saf,Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS
#11175,10.1016/j.vaccine.2024.04.070,38670844,,,Xie 2024,2024,Vaccine,COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population
#9595,10.3390/vaccines12040425,38675807,PMC11054385,,Riccomi 2024,2024,Vaccines,Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination
#11344,10.1016/j.jri.2024.104246,38677139,,,Youngster 2024,2024,J Reprod Immunol,The effect of COVID-19 vaccination during IVF stimulation on cycle outcomes- a retrospective cohort study
#8321,10.1016/j.ajog.2024.04.028,38697336,,,Magnus 2024,2024,Am J Obstet Gynecol,COVID-19 vaccination during pregnancy is not associated with an increased risk of severe postpartum hemorrhage
#19001,10.1016/j.jvacx.2024.100489,38699157,PMC11063515,,Tani 2024,2024,Vaccine X,Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations
#13170,10.1016/s1473-3099(24)00215-9,38701823,,,Ares-Gómez 2024,2024,Lancet Infect Dis,"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study"
#11161,10.1016/j.ijid.2024.107080,38701913,,,Xiang 2024,2024,Int J Infect Dis,Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study using data from the UK Biobank
#10101,10.1016/j.vaccine.2024.04.051,38704258,,,Shi 2024,2024,Vaccine,Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older
#10264,10.1016/j.vaccine.2024.04.096,38714447,,,Soe 2024,2024,Vaccine,mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network
#7563,10.1016/j.jinf.2024.106177,38719110,,,Kirsebom 2024,2024,J Infect,"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study"
#871,10.1016/j.gastrohep.2024.502202,38723765,,,daSilva 2025,2025,Gastroenterol Hepatol,Vaccine adherence and adverse events of the SARS-COV vaccine in patients with inflammatory bowel disease
#5982,10.1016/j.eprac.2024.05.001,38729568,,,Duskin-Bitan 2024,2024,Endocr Pract,Subacute Thyroiditis Following COVID-19 and COVID-19 Vaccination
#10032,10.1016/j.vaccine.2024.04.097,38729910,,,Shani 2024,2024,Vaccine,The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities
#6524,10.1016/s2665-9913(24)00065-1,38734019,,,Goodyear 2024,2024,Lancet Rheumatol,"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial"
#11174,10.1001/jama.2024.7395,38748411,PMC11097092,,Xie 2024,2024,Jama,Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024
#4622,10.1016/j.vaccine.2024.05.009,38762360,PMC11252665,,AnnCostaClemens 2024,2024,Vaccine,Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice
#5520,10.1111/petr.14786,38766983,,,Churilla 2024,2024,Pediatr Transplant,Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study
#17803,10.1097/txd.0000000000001645,38769974,,,Petr 2024,2024,Transplant Direct,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study
#19530,10.1111/irv.13284,38773753,PMC11109477,,Whitaker 2024,2024,Influenza Other Respir Viruses,Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom
#5392,10.1016/j.ijid.2024.107095,38777080,,,Chemaitelly 2024,2024,Int J Infect Dis,Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar
#10367,10.1097/aog.0000000000005615,38781590,,,Strid 2024,2024,Obstet Gynecol,Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System
#15668,10.1002/jmv.29682,38783823,,,Jeong 2024,2024,J Med Virol,"Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database"
#4454,10.1002/hsr2.2142,38784253,PMC11112633,,Al-Haddad 2024,2024,Health Science Reports,The impact of SARS-CoV-2 mRNA vaccine on intracytoplasmic sperm injection outcomes at a fertility center in Iraq: A prospective cohort study
#28053,10.1038/s41467-024-47745-z,38802362,PMC11130197,,Copland 2024,2024,Nat Commun,Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
#9658,10.1093/qjmed/hcae103,38806183,,,Roh 2024,2024,Qjm,A potential association between COVID-19 vaccination and development of Alzheimer's disease
#6143,10.1136/ard-2024-225869,38816065,PMC11503143,,Farisogullari 2024,2024,Ann Rheum Dis,Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
#6348,10.1002/ohn.833,38822762,,,Gallagher 2024,2024,Otolaryngol Head Neck Surg,Association of COVID-19 Vaccination With Changes in Smell and Taste
#16179,10.1016/j.xops.2024.100474,38827031,PMC11141252,,Kumar 2024,2024,Ophthalmol Sci,Risk of Recurrent Noninfectious Uveitis After Coronavirus Disease 2019 Vaccination in the United States
#7803,10.2196/47070,38833299,PMC11185909,,Lang 2024,2024,J Med Internet Res,COVID-19 Vaccine Effectiveness and Digital Pandemic Surveillance in Germany (eCOV Study): Web Application-Based Prospective Observational Cohort Study
#10952,10.3389/fphar.2024.1374320,38841369,PMC11150672,,Wang 2024,2024,Frontiers in Pharmacology,COVID-19 vaccination-related tinnitus is associated with pre-vaccination metabolic disorders
#5806,10.1097/aog.0000000000005632,38843526,,,Denoble 2024,2024,Obstet Gynecol,Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink
#15013,10.1002/ski2.367,38846690,PMC11150739,,Gordon 2024,2024,Skin Health Dis,Exploring cutaneous lymphoproliferative disorders in the wake of COVID-19 vaccination
#4590,10.1093/infdis/jiae291,38848312,PMC11481330,,Amstutz 2024,2024,J Infect Dis,Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
#9075,10.1016/j.vaccine.2024.06.009,38853036,,,Otsuki 2024,2024,Vaccine,Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial
#5983,10.7326/m23-2956,38857503,,,Dutcher 2024,2024,Ann Intern Med,COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study
#5560,10.1136/archdischild-2024-327153,38857952,PMC11347209,,Coma 2024,2024,Arch Dis Child,Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)
#5402,10.1186/s12916-024-03457-1,38858672,PMC11165729,,Chen 2024,2024,BMC Med,"Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England"
#16358,10.1002/jmv.29693,38859751,,,Lee 2024,2024,J Med Virol,Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database
#10083,10.1093/jpids/piae062,38860591,PMC11344470,,Sher 2024,2024,J Pediatric Infect Dis Soc,Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds
#6041,10.1093/ofid/ofae287,38868305,PMC11167675,,Elbaz 2024,2024,Open Forum Infectious Diseases,Varicella-Zoster Virus-Induced Neurologic Disease After COVID-19 Vaccination: A Multicenter Observational Cohort Study
#11317,10.1186/s13293-024-00625-z,38890702,PMC11184791,,Yin 2024,2024,Biol Sex Differ,Sex and gender differences in adverse events following influenza and COVID-19 vaccination
#8844,10.1136/bmjgast-2024-001370,38897611,PMC11200233,,Nakafero 2024,2024,BMJ Open Gastroenterology,"Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: A UK-wide study"
#5454,10.1016/j.vaccine.2024.06.042,38897892,,,Cheng 2024,2024,Vaccine,Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine
#4916,10.1007/s40264-024-01449-x,38907947,PMC11399172,,Bellitto 2024,2024,Drug Saf,"What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European ""Covid Vaccine Monitor"" Active Surveillance Study"
#10883,10.1016/j.ijid.2024.107149,38909928,,,Wan 2024,2024,Int J Infect Dis,Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
#6236,10.1016/j.vaccine.2024.06.045,38910092,,,Fitzpatrick 2024,2024,Vaccine,Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study
#4486,10.1007/s00431-024-05634-z,38910199,,,Alejandre 2024,2024,Eur J Pediatr,Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care
#9740,10.3346/jkms.2024.39.e190,38915282,PMC11196855,,Ryu 2024,2024,J Korean Med Sci,Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea
#11193,10.2196/53807,38916940,PMC11234065,,Xu 2024,2024,JMIR Public Health Surveill,Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study
#5494,10.1093/cid/ciae339,38922669,,,Chong 2024,2024,Clin Infect Dis,Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study
#10470,10.1111/apa.17329,38923614,,,Tamir-Hostovsky 2024,2024,Acta Paediatr,Association of BNT162b2 SARS-CoV-2 vaccination during pregnancy with postnatal outcomes in premature infants
#6931,10.3390/medicina60060956,38929574,PMC11206152,,HospitalEspañoldePachucaResearch 2024,2024,Medicina (Kaunas),Anti-COVID-19 Vaccination Alters the Menstrual Cycle and Dose Accumulation Enhances the Effect
#7937,10.3390/vaccines12060593,38932322,PMC11209536,,Leung 2024,2024,Vaccines,Risk of Seizure Aggravation after COVID-19 Vaccinations in Patients with Epilepsy
#6361,10.1002/brb3.3587,38940313,PMC11212002,,Ganelin-Cohen 2024,2024,Brain Behav,The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI
#7705,10.1097/md.0000000000038771,38941384,,,Küçükerdem 2024,2024,Medicine (Baltimore),Evaluation of menstrual irregularities following COVID-19 infection or vaccination: The impact of COVID anxiety and associated risk factors
#5758,10.1007/s40264-024-01456-y,38949714,PMC11485106,,delaCueva 2024,2024,Drug Saf,"Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season"
#7774,10.1080/21645515.2024.2368681,38953297,PMC11221462,,Lafleur 2024,2024,Hum Vaccin Immunother,Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study
#2667,10.1016/j.jiac.2024.06.023,38959995,,,Nakayama 2025,2025,J Infect Chemother,"The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study"
#763,10.1093/infdis/jiae342,38970327,PMC11793055,,Chime 2025,2025,J Infect Dis,"Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine"
#5191,10.1007/s40121-024-00985-4,38981954,PMC11266338,,Buynak 2024,2024,Infectious Diseases and Therapy,"Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65"
#5779,10.3389/fmed.2024.1338317,38983365,PMC11231098,,de-la-Plaza-San-Frutos 2024,2024,Frontiers in Medicine,Effects of vaccination against COVID-19 on overactive bladder symptoms on young population
#8092,10.21315/mjms2024.31.3.10,38984235,PMC11229573,,Lin 2024,2024,Malaysian Journal of Medical Sciences,Risk Factors Associated with Cutaneous Reactions Following COVID-19 Vaccine Immunisation: A Registry-Based Case-Control Study
#7598,10.24171/j.phrp.2024.0081,38988090,PMC11391368,,Ko 2024,2024,Osong Public Health and Research Perspectives,Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
#8588,10.1097/aog.0000000000005670,38991216,,,Metz 2024,2024,Obstet Gynecol,Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy
#5488,10.1093/eurheartj/ehae335,38993069,,,Choi 2024,2024,Eur Heart J,Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study
#2008,10.1016/j.therap.2024.06.003,38997859,,,Lacroix 2025,2025,Therapie,"COVACPREG, a French prospective cohort study of women vaccinated against COVID-19 during pregnancy"
#16712,10.3390/healthcare12131250,38998785,PMC11241583,,Lu 2024,2024,Healthcare (Basel),Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan
#7421,10.1016/j.resinv.2024.07.004,39002293,,,Kawana 2024,2024,Respir Investig,Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients
#9295,10.1016/j.vaccine.2024.06.057,39003104,,,Pham-Huy 2024,2024,Vaccine,Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center
#7142,10.1016/j.vaccine.2024.07.031,39004527,,,Jajou 2024,2024,Vaccine,GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands
#7743,10.3892/etm.2024.12626,39006455,PMC11240278,,Kuwano 2024,2024,Experimental and Therapeutic Medicine,Diagnostic features of autoimmune hepatitis in SARS_CoV_2_vaccinated vs. unvaccinated individuals
#8025,10.2196/51007,39008362,PMC11287098,,Li 2024,2024,JMIR Public Health Surveill,Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis
#19019,10.1093/ofid/ofae370,39015348,PMC11250225,,Tartof 2024,2024,Open Forum Infect Dis,Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages
#7943,10.1093/infdis/jiae364,39028664,,,Levy 2024,2024,J Infect Dis,Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 Variant
#11603,10.1111/irv.13331,39031876,PMC11190946,,ZornozaMoreno 2024,2024,Influenza Other Respir Viruses,"Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain"
#8238,10.1001/jamanetworkopen.2024.23926,39037818,PMC11265121,,Lu 2024,2024,JAMA Netw Open,"Stroke After Influenza Vaccines in Older Adults in the US, 2016 to 2019"
#7297,10.1038/s41467-024-50656-8,39039113,PMC11263712,,Jung 2024,2024,Nat Commun,"Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study"
#5811,10.1111/jce.16372,39039649,,,Deshmukh 2024,2024,J Cardiovasc Electrophysiol,Association between COVID-19 vaccination and atrial arrhythmias in individuals with cardiac implantable electronic devices
#10550,10.1016/j.jvacx.2024.100516,39040886,PMC11260603,,Tetsuka 2024,2024,VACCINE: X,Adverse events of COVID-19 vaccination during 2021–2022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students
#6193,10.1007/s11739-024-03641-4,39042210,,,Ferrari 2024,2024,Intern Emerg Med,Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting
#9105,10.1007/s00266-024-04274-w,39046483,,,Padilla-Pantoja 2024,2024,Aesthetic Plast Surg,Temporary Delayed Hypersensitivity Reaction to Botulinum Toxin-A After COVID-19 Vaccination: A Case Series
#4933,10.1093/infdis/jiad508,39052718,PMC11272042,,Bennett 2024,2024,J Infect Dis,Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial
#6167,10.1093/infdis/jiad539,39052720,PMC11272077,,Fell 2024,2024,J Infect Dis,"Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada"
#33721,10.3390/vaccines12070790,39066428,PMC11281408,,Mundorf 2024,2024,Vaccines (Basel),Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS)
#9701,10.3390/vaccines12070802,39066440,PMC11281689,,Rousculp 2024,2024,Vaccines (Basel),"Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines"
#8703,10.1007/s40264-024-01462-0,39068268,PMC11485117,,Morciano 2024,2024,Drug Saf,Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study
#11385,10.2147/IJGM.S467586,39070223,PMC11283260,,Zahrani 2024,2024,International Journal of General Medicine,"Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study"
#15356,10.7759/cureus.63410,39070394,PMC11283873,,Hikichi 2024,2024,Cureus,Comparison of Transient and Persistent Adverse Events After COVID-19 Vaccination: A Retrospective Analysis
#11376,10.1016/j.jcv.2024.105718,39079210,PMC11384212,,Yunker 2024,2024,J Clin Virol,"Genomic evolution of influenza during the 2023-2024 season, the johns hopkins health system"
#7078,10.1038/s41467-024-49634-x,39085208,PMC11291640,,Ip 2024,2024,Nat Commun,Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
#6208,10.1016/j.eclinm.2024.102720,39091673,PMC11293523,,Figueroa 2024,2024,eClinicalMedicine,Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial
#17692,10.12669/pjms.40.7.8709,39092064,PMC11255808,,Parveen 2024,2024,Pak J Med Sci,COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan
#7882,10.1016/j.mayocp.2024.03.026,39093271,,,Lee 2024,2024,Mayo Clin Proc,COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study
#11312,10.1016/j.amjoto.2024.104448,39096568,PMC11634645,,Yih 2024,2024,Am J Otolaryngol,Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink
#5532,10.1093/cid/ciae365,39099085,PMC11478588,,Clark 2024,2024,Clin Infect Dis,Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
#6180,10.1093/cid/ciae364,39099093,PMC11478578,,Ferguson 2024,2024,Clin Infect Dis,Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age
#4340,10.2147/IJGM.S466838,39100722,PMC11297544,,Abukhalil 2024,2024,International Journal of General Medicine,COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine
#3634,10.1016/j.jiac.2024.07.025,39103148,,,Takada 2025,2025,J Infect Chemother,SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database
#32816,10.1093/cid/ciae405,39107255,,,Ma 2024,2024,Clin Infect Dis,"Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024"
#17350,10.1016/j.heliyon.2024.e34347,39108860,PMC11301373,,Namiki 2024,2024,Heliyon,Comparison of adverse events following the second/third dose of BNT162b2 in a medical institute in Japan
#6376,10.1016/j.vaccine.2024.126182,39116486,,,Gao 2024,2024,Vaccine,"Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial"
#5888,10.1016/j.ijid.2024.107202,39122207,,,Domnich 2024,2024,Int J Infect Dis,Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study
#5400,10.3390/jcm13154494,39124761,PMC11313347,,Chen 2024,2024,Journal of Clinical Medicine,De Novo Biopsy-Proven Glomerular Disease Following COVID-19 Vaccination
#11227,10.3389/fpubh.2024.1406315,39139673,PMC11320210,,Yamamoto 2024,2024,Front Public Health,Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis
#8672,10.1212/wnl.0000000000209662,39141880,,,Moisset 2024,2024,Neurology,Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series
#7400,10.7774/cevr.2024.13.3.218,39144130,PMC11319113,,Katatbeh 2024,2024,Clinical and Experimental Vaccine Research,Incidence of narcolepsy symptoms after taking COVID-19 vaccines: a Jordanian cross-sectional study
#4633,10.1111/irv.13360,39145535,PMC11325250,,Antunes 2024,2024,Influenza Other Respir Viruses,"Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024"
#9319,10.1089/vim.2024.0019,39149804,,,Pinto 2024,2024,Viral Immunol,Comparison of Adverse Events and Antibody Responses Among Different COVID-19 Vaccination Schedules
#9228,10.1016/j.jadohealth.2024.06.023,39152975,PMC11490362,,Payne 2024,2024,J Adolesc Health,A Prospective Study of the Relationship of COVID-19 Vaccination to Menstrual Cycle Characteristics in Adolescent Girls
#4960,10.1093/cid/ciae420,39158584,PMC11650855,,Berthaud 2024,2024,Clin Infect Dis,Safety and Immunogenicity of an mRNA-1273 Booster in Children
#17515,10.1111/1756-185x.15294,39171515,,,Oh 2024,2024,Int J Rheum Dis,"Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database"
#8873,10.1093/ehjcvp/pvae063,39174484,,,Nazar 2024,2024,Eur Heart J Cardiovasc Pharmacother,Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data
#6561,10.3389/fphar.2024.1376474,39175548,PMC11338880,,GranjaLópez 2024,2024,Frontiers in Pharmacology,Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study
#10114,10.1016/j.vaccine.2024.126241,39178768,,,Shinjoh 2024,2024,Vaccine,Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures
#1629,10.1016/j.ajo.2024.08.015,39179130,,,Hwang 2025,2025,Am J Ophthalmol,COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population
#19817,10.1038/s43856-024-00588-7,39181950,PMC11344792,,Yechezkel 2024,2024,Commun Med (Lond),Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination
#18485,10.1001/jama.2024.16380,39186694,PMC11348078,,Semenzato 2024,2024,Jama,"Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies"
#6099,10.3390/ijerph21081090,39200699,PMC11354165,,Esteban-Cledera 2024,2024,Int J Environ Res Public Health,"Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain"
#8394,10.3390/medicina60081343,39202624,PMC11356762,,Manniche 2024,2024,Medicina (Kaunas),Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden
#11585,10.3390/vaccines12080935,39204058,PMC11360506,,Zhu 2024,2024,Vaccines,Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older
#5255,10.1016/s2352-4642(24)00171-8,39208832,,,Carbajal 2024,2024,Lancet Child Adolesc Health,"Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France"
#8593,10.1080/21645515.2024.2394255,39208849,PMC11364069,,Mi 2024,2024,Hum Vaccin Immunother,"Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
#4774,10.1038/s41467-024-50376-z,39209823,PMC11362294,,Baden 2024,2024,Nat Commun,Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
#10568,10.1093/cid/ciad458,39219510,PMC10724468,,Thomas 2023,2023,Clin Infect Dis,Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients
#4837,10.3389/fpubh.2024.1441786,39220460,PMC11361977,,BarbasDelBuey 2024,2024,Front Public Health,The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study
#6372,10.1093/ofid/ofae456,39220659,PMC11365065,,Gào 2024,2024,Open Forum Infectious Diseases,"Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
#8481,10.1177/20503121241272518,39220747,PMC11363057,,Matsuzono 2024,2024,SAGE Open Medicine,Effect of COVID 19 pandemic on the neurology department hospitalization with analysis of the neurological complications secondary to COVID 19 and vaccination against COVID 19
#2023,10.1080/23744235.2024.2399108,39226235,,,Lambo 2025,2025,Infect Dis (Lond),"The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaçao, the Caribbean"
#10420,10.1001/jama.2024.15775,39230920,PMC11375516,,Surie 2024,2024,Jama,RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older
#7847,10.1038/s41467-024-52038-6,39232036,PMC11374778,,LeVu 2024,2024,Nat Commun,Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis
#5478,10.1002/pds.70006,39238434,,,Cho 2024,2024,Pharmacoepidemiol Drug Saf,Association Between Influenza Vaccination and Acute Kidney Injury Among the Elderly: A Self-Controlled Case Series
#11107,10.1016/j.vaccine.2024.126290,39241357,PMC12136157,,Woo 2024,2024,Vaccine,Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)
#5023,10.1016/j.vaccine.2024.126305,39244425,,,Blasco 2024,2024,Vaccine,Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome
#9013,10.1016/j.jamda.2024.105251,39245233,,,Okoye 2024,2024,J Am Med Dir Assoc,Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study
#2762,10.5858/arpa.2024-0095-OA,39246098,,,Obeng 2025,2025,Arch Pathol Lab Med,Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines
#1109,10.1007/s00592-024-02372-4,39254746,,,Engelbogen 2025,2025,Acta Diabetol,SARS-CoV-2 booster vaccination does not worsen glycemia in people with type 1 diabetes using insulin pumps: an observational study
#5883,10.1542/peds.2024-066508,39257380,,,Domachowske 2024,2024,Pediatrics,Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children
#8982,10.29399/npa.28418,39258123,PMC11382557,,Öcek 2024,2024,Noropsikiyatri Arsivi,Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis
#9546,10.1016/j.vaccine.2024.126256,39260053,PMC11911014,,Regan 2024,2024,Vaccine,Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study
#10752,10.1016/j.vaccine.2024.126273,39276619,,,vanHeesbeen 2024,2024,Vaccine,"Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study"
#328,10.1093/infdis/jiae454,39279435,PMC11793066,,Bahakel 2025,2025,J Infect Dis,Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season
#8569,10.1111/1471-0528.17949,39279662,,,Mensah 2024,2024,Bjog,"COVID-19 Vaccine Safety in Pregnancy, A Nested Case-Control Study in Births From April 2021 to March 2022, England"
#9241,10.1007/s12026-024-09540-2,39285049,,,Pekdiker 2024,2024,Immunol Res,ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?
#13419,10.1177/10781552241285034,39285730,,,BenKridis 2024,2024,J Oncol Pharm Pract,Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study
#1913,10.1080/09286586.2024.2399345,39288331,,,Kim 2025,2025,Ophthalmic Epidemiol,Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study
#7139,10.1016/j.eclinm.2024.102809,39290640,PMC11406334,,Jain 2024,2024,eClinicalMedicine,Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study
#10431,10.1093/ofid/ofae495,39290777,PMC11406745,,Swift 2024,2024,Open Forum Infectious Diseases,"Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras"
#448,10.1016/j.therap.2024.08.002,39294069,,,Beurrier 2025,2025,Therapie,Retinal vascular occlusion after COVID-19 vaccination: Analysis of the French pharmacovigilance database
#13702,10.1016/j.eclinm.2024.102815,39296584,PMC11408803,,Camporesi 2024,2024,EClinicalMedicine,Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study
#6443,10.1001/jamanetworkopen.2024.34857,39298167,PMC11413712,,Getahun 2024,2024,JAMA Netw Open,Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies
#6266,10.1016/j.vaccine.2024.126375,39298999,,,Fotakis 2024,2024,Vaccine,Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024)
#9233,10.4103/singaporemedj.SMJ-2023-258,39324928,,,Peck 2024,2024,Singapore Med J,Anaphylaxis post-COVID-19 vaccinations in Singapore
#6794,10.15585/mmwr.mm7338a1,39325677,PMC11563568,,Havers 2024,2024,MMWR Morb Mortal Wkly Rep,"COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months - COVID-NET, 12 States, October 2022-April 2024"
#8693,10.1186/s13293-024-00651-x,39327617,PMC11426002,,Moor 2024,2024,Biol Sex Differ,Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study
#1212,10.1016/s1473-3099(24)00501-2,39332418,,,Figueroa 2025,2025,Lancet Infect Dis,"Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial"
#9582,10.3390/vaccines12090971,39340003,PMC11435866,,Reynolds 2024,2024,Vaccines (Basel),Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia
#6947,10.3390/vaccines12090983,39340015,PMC11435606,,Hrycek 2024,2024,Vaccines,The Influence of SARS-CoV-2 Vaccination on the Mortality and Outcomes of Patients with Both Myocardial Infarction and COVID-19
#9320,10.3390/vaccines12091016,39340046,PMC11436231,,Pira 2024,2024,Vaccines,COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid
#7564,10.1016/j.jinf.2024.106293,39343245,,,Kirwan 2024,2024,J Infect,Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024
#4932,10.1016/j.jinf.2024.106285,39343247,,,Bennett 2024,2024,J Infect,Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial
#5393,10.1111/irv.13357,39343986,PMC11439586,,Chemaitelly 2024,2024,Influenza Other Respir Viruses,BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar
#4039,10.1093/eurheartj/ehae639,39344920,PMC11704415,,Xu 2025,2025,Eur Heart J,Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study
#11414,10.15585/mmwr.mm7339a1,39361525,PMC11449270,,Zeno 2024,2024,MMWR Morb Mortal Wkly Rep,"Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024"
#10522,10.15585/mmwr.mm7339a2,39361542,PMC11449267,,Taylor 2024,2024,MMWR Morb Mortal Wkly Rep,"COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥18 Years - COVID-NET, 12 States, October 2023-April 2024"
#7951,10.1038/s41467-024-52668-w,39362845,PMC11450198,,Lewnard 2024,2024,Nat Commun,Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage
#9276,10.2807/1560-7917.Es.2024.29.40.2400618,39364601,,,Pérez-Gimeno 2024,2024,Euro Surveill,"Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24"
#22595,10.1159/000541797,39369714,PMC11805550,,Kyung 2025,2025,Med Princ Pract,"Global and Regional Burden of Vaccine-Associated Erythema Multiforme and Their Related Vaccines, 1967-2023: An In-Depth Analysis of the World Health Organization Pharmacovigilance Database"
#7105,10.1038/s41598-024-73004-8,39375365,PMC11458568,,Itamochi 2024,2024,Sci Rep,COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents
#11335,10.3201/eid3011.240610,39378869,PMC11521192,,Yoon 2024,2024,Emerg Infect Dis,"Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021-2022"
#7737,10.24953/turkjpediatr.2024.4512,39387432,,,Kurucu 2024,2024,Turk J Pediatr,Safety and efficacy of COVID-19 vaccines in children and adolescents with cancer
#9334,10.23736/s0026-4806.24.09379-0,39392292,,,P_atkowska-Adamska 2024,2024,Minerva Med,BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy
#5609,10.1016/j.tjnut.2024.09.032,39396761,PMC11662230,,Couvillion 2024,2024,J Nutr,Associations between SARS-CoV-2 Infection or COVID-19 Vaccination and Human Milk Composition: A Multi-Omics Approach
#10617,10.1016/j.vaccine.2024.126445,39413493,,,Top 2024,2024,Vaccine,Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study
#7327,10.1016/j.jaut.2024.103325,39413503,,,Kälin 2024,2024,J Autoimmun,SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases
#9734,10.1016/j.medcli.2024.07.023,39414550,,,RuzafaMartinez 2024,2024,Med Clin (Barc),Vaccine effectiveness in patients admitted for influenza during the 2023-2024 season
#6318,10.1016/j.jiph.2024.102562,39418956,,,Fuller 2024,2024,J Infect Public Health,"Sex, vaccination status, and comorbidities influence long COVID persistence"
#5193,10.1038/s41598-024-73940-5,39420039,PMC11487014,,Byoun 2024,2024,Sci Rep,Nationwide Cohort observational study on the safety and efficacy of COVID-19 vaccination in patients with Moyamoya disease
#4476,10.2147/IJWH.S472953,39421715,PMC11484768,,Alawfi 2024,2024,International Journal of Women's Health,Health of Saudi Women in the Post-Pandemic Era: Candidiasis Incidence and Post COVID-19 and COVID-19-Vaccination
#9227,10.1016/s0140-6736(24)01738-0,39426837,,,Payne 2024,2024,Lancet,"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis"
#7190,10.1038/s41598-024-74729-2,39427003,PMC11490553,,Jeong 2024,2024,Sci Rep,Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023
#7370,10.1186/s12889-024-20297-z,39434043,PMC11495130,,Karam 2024,2024,BMC Public Health,Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database
#7545,10.3349/ymj.2023.0354,39439166,PMC11519129,,Kim 2024,2024,Yonsei Med J,Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
#10043,10.1016/j.vaccine.2024.126440,39442285,,,Sharff 2024,2024,Vaccine,Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system
#11375,10.1017/s0950268824001213,39444354,,,Yun 2024,2024,Epidemiol Infect,The impact of COVID-19 status and vaccine type following the first dose on acute heart disease: A nationwide retrospective cohort study in South Korea
#7666,10.1080/21645515.2024.2416329,39445787,PMC11508945,,Kothari 2024,2024,Hum Vaccin Immunother,"A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months"
#9910,10.1001/jamanetworkopen.2024.40817,39446325,PMC11581605,,Schmader 2024,2024,JAMA Netw Open,Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine: A Randomized Clinical Trial
#8278,10.15585/mmwr.mm7342a1,39446667,PMC11500842,,Ma 2024,2024,MMWR Morb Mortal Wkly Rep,"Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages - United States, May 2023-September 2024"
#4303,10.1016/j.vaccine.2024.126465,39447251,,,AbRahman 2024,2024,Vaccine,"Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study"
#5696,10.1016/j.vaccine.2024.126460,39447252,,,Darko 2024,2024,Vaccine,Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study
#8892,10.1016/j.vaccine.2024.126462,39454292,,,Ng 2024,2024,Vaccine,Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore
#7191,10.3390/jcm13206173,39458123,PMC11508506,,J__kowiak-Kossakowska 2024,2024,Journal of Clinical Medicine,Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland
#38922,10.3390/vaccines12101160,39460326,PMC11510999,,JimenoRuiz 2024,2024,Vaccines,Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain.
#2779,10.1016/s1473-3099(24)00565-6,39461355,,,Okada 2025,2025,Lancet Infect Dis,Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
#11416,10.1016/j.jvacx.2024.100571,39474208,PMC11513630,,Zethelius 2024,2024,Vaccine X,Pulmonary embolism after SARS-CoV-2 vaccination
#5079,10.1093/ofid/ofae597,39474445,PMC11521338,,Bosch 2024,2024,Open Forum Infectious Diseases,"Incidence of Respiratory Syncytial Virus in Community-Dwelling Adults Aged 18-64 Years Over 2 Seasons, 2022-2024, in a North American Community"
#6384,10.1016/j.nrleng.2024.10.001,39488251,,,García-Azorín 2024,2024,Neurologia (Engl Ed),Thrombosis with thrombocytopenia syndrome following adenovirus vector-based vaccines to prevent COVID-19: Epidemiology and clinical presentation in Spain
#5200,10.1038/s41467-024-53842-w,39488521,PMC11531596,,Caffrey 2024,2024,Nat Commun,Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
#9407,10.3389/fcvm.2024.1435038,39494234,PMC11527644,,Pudasaini 2024,2024,Frontiers in Cardiovascular Medicine,Levels of high-sensitive troponin T and mid-regional pro-adrenomedullin after COVID-19 vaccination in vulnerable groups: monitoring cardiovascular safety of COVID-19 vaccination
#8970,10.1093/ofid/ofae557,39494453,PMC11530954,,O'Carroll 2024,2024,Open Forum Infectious Diseases,Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk
#9154,10.3346/jkms.2024.39.e274,39497564,PMC11538574,,Park 2024,2024,J Korean Med Sci,Reported Adverse Events and Associated Factors in Korean Coronavirus Disease 2019 Vaccinations
#8320,10.1007/s10654-024-01170-0,39503924,PMC11599392,,Magnus 2024,2024,Eur J Epidemiol,Covid-19 vaccination and menstrual bleeding disturbances among women of fertile age: a Norwegian registry study
#10879,10.1001/jamanetworkopen.2024.43166,39504023,PMC11541642,,Walter 2024,2024,JAMA Netw Open,Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial
#5464,10.1371/journal.pone.0310781,39509358,PMC11542819,,Chewaskulyong 2024,2024,PLoS One,Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients
#6950,10.1016/j.xagr.2024.100395,39512761,PMC11541679,,Hsiao 2024,2024,AJOG Global Reports,Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants
#9126,10.1038/s41541-024-00964-3,39516206,PMC11549351,,Pan 2024,2024,npj Vaccines,Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study
#907,10.1093/cid/ciae550,39523547,PMC12043053,,Davis 2025,2025,Clin Infect Dis,Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions
#8576,10.1111/irv.70009,39523781,PMC11551475,,Merdrignac 2024,2024,Influenza Other Respir Viruses,"Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024"
#7241,10.7774/cevr.2024.13.4.309,39525675,PMC11543796,,Jirawattanadon 2024,2024,Clinical and Experimental Vaccine Research,"Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination"
#1574,10.1007/s15010-024-02427-2,39527343,PMC11971181,,Holzwarth 2025,2025,Infection,PaedVacCOVID - safety of the BNT162b2 vaccine against the SARS-CoV-2 in children with and without comorbidities aged 5 to 11 years
#8955,10.1080/14760584.2024.2428800,39535047,,,Nunes 2024,2024,Expert Rev Vaccines,Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR Network Study
#1705,10.1016/j.vaccine.2024.126514,39536455,,,Jastorff 2025,2025,Vaccine,"Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial"
#9151,10.3346/jkms.2024.39.e309,39536790,PMC11557253,,Park 2024,2024,J Korean Med Sci,Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea
#10945,10.1080/21645515.2024.2425149,39540202,PMC11572236,,Wang 2024,2024,Hum Vaccin Immunother,"Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial"
#7907,10.15585/mmwr.mm7345a1,39541241,PMC11576050,,Lefferts 2024,2024,MMWR Morb Mortal Wkly Rep,"Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024"
#8535,10.1016/j.jinf.2024.106346,39550007,,,McLeod 2024,2024,J Infect,"The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old"
#17357,10.7759/cureus.71671,39553063,PMC11568403,,Naqid 2024,2024,Cureus,"Evaluating the Adverse Effects and Associated Risk Factors of COVID-19 Vaccines Among Healthcare Workers: A Retrospective Study in the Duhok Province, Iraq"
#17051,,39555720,,https://imj.ie/wp-content/uploads/2024/10/Cardiac-Investigations-in-Paediatric-Patients-with-Chest-Pain-Following-COVID-19-mRNA-Vaccination.pdf,Memon 2024,2024,Ir Med J,Cardiac Investigations in Paediatric Patients with Chest Pain Following COVID-19 mRNA Vaccination
#5486,10.24171/j.phrp.2024.0194,39557576,PMC11700711,,Choi 2024,2024,Osong Public Health and Research Perspectives,Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea
#6425,10.1186/s12879-024-10226-1,39558292,PMC11572516,,Gennaro 2024,2024,BMC Infect Dis,"Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study"
#3241,10.1007/s10072-024-07870-5,39560882,,,Salmaggi 2025,2025,Neurol Sci,Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis
#15755,10.1136/bmjmed-2023-000743,39574424,PMC11579536,,Jorgensen 2024,2024,BMJ Med,Association between maternal mRNA covid-19 vaccination in early pregnancy and major congenital anomalies in offspring: population based cohort study with sibling matched analysis
#16794,10.1001/jamanetworkopen.2024.47492,39585698,PMC11589793,,Madni 2024,2024,JAMA Netw Open,COVID-19 Vaccine Reactogenicity Among Young Children
#10585,10.3390/vaccines12111237,39591140,PMC11599008,,Tian 2024,2024,Vaccines,Protective Impact of Influenza Vaccination on Healthcare Workers
#782,10.1016/j.vaccine.2024.126506,39591703,,,Choi 2025,2025,Vaccine,The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination
#1388,10.1016/s1473-3099(24)00589-9,39608389,,,Goswami 2025,2025,Lancet Infect Dis,"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial"
#15830,10.4168/aair.2024.16.6.613,39622686,PMC11621480,,Kang 2024,2024,Allergy Asthma Immunol Res,"Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database"
#8432,10.1111/irv.70023,39623514,PMC11611713,,Marron 2024,2024,Influenza Other Respir Viruses,Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland
#1648,10.1016/j.ijid.2024.107324,39637971,,,Ip 2025,2025,Int J Infect Dis,COVID-19 vaccination and cerebral small vessel disease progression-A prospective cohort study
#525,10.1007/s40264-024-01495-5,39638989,PMC11829932,,Boulefaa 2025,2025,Drug Saf,Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database
#2378,10.1016/j.vaccine.2024.126569,39643572,,,Marchese 2025,2025,Vaccine,"Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)"
#3260,10.1016/j.vaccine.2024.126535,39645433,,,Sankar 2025,2025,Vaccine,Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening
#2559,10.1001/jamapediatrics.2024.5572,39652359,PMC11667569,,Moline 2025,2025,JAMA Pediatr,Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
#3468,10.5694/mja2.52557,39655683,,,Smith 2025,2025,Med J Aust,"Clinical phenotype of COVID-19 vaccine-associated myocarditis in Victoria, 2021-22: a cross-sectional study"
#4651,10.1093/cid/ciae596,39656748,,,Arbetter 2024,2024,Clin Infect Dis,Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
#19044,10.1093/cid/ciae597,39656838,PMC12287760,,Tenforde 2024,2024,Clin Infect Dis,"Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
#3937,10.1093/cid/ciae598,39657038,,,Wee 2025,2025,Clin Infect Dis,Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study
#13386,10.1210/clinem/dgae858,39657695,,,Bea 2024,2024,J Clin Endocrinol Metab,The Impact of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients
#2557,10.1016/j.jinf.2024.106374,39657850,,,Mok 2025,2025,J Infect,Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine
#18764,10.1016/j.lana.2024.100949,39659558,PMC11629564,,Soe 2024,2024,Lancet Reg Health Am,mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
#1635,10.1016/j.cmi.2024.12.002,39662823,,,Iba 2025,2025,Clin Microbiol Infect,Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study
#19017,10.1001/jamanetworkopen.2024.49944,39666343,PMC11638790,,Tartof 2024,2024,JAMA Netw Open,BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age
#10113,10.1080/21645515.2024.2425147,39666396,PMC11789733,,Shinde 2024,2024,Hum Vaccin Immunother,Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M(TM) adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
#5539,10.2807/1560-7917.Es.2024.29.50.2400164,39668765,,,Clothier 2024,2024,Euro Surveill,"Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023"
#10507,10.1001/jamanetworkopen.2024.50832,39671195,PMC11645642,,Tartof 2024,2024,JAMA Netw Open,Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease
#3481,10.1016/j.bbih.2024.100902,39686920,PMC11646749,,Sodagari 2025,2025,"Brain, Behavior, and Immunity - Health",Examining vaccination-related adverse events in frequent neurodegenerative diseases
#2405,10.1016/j.ijid.2024.107364,39694231,PMC11735411,,Martínez-Baz 2025,2025,Int J Infect Dis,"Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study"
#3592,10.1016/j.vaccine.2024.126629,39700907,,,Sun 2025,2025,Vaccine,Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States
#2089,10.1080/21645515.2024.2435156,39704470,,,Lei 2025,2025,Hum Vaccin Immunother,"Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
#3972,10.1101/2025.03.27.25324770v1,39708059,,,Wilson 2025,2025,Infect Dis Ther,Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged ≥ 18 years in the United States
#4409,10.3346/jkms.2024.39.e317,39716863,PMC11666327,,Ahn 2024,2024,J Korean Med Sci,Epidemiological Characteristics and Outcome of Myocarditis and Pericarditis Temporally Associated With BNT162b2 COVID-19 Vaccine in Adolescents: Korean National Surveillance
#25149,10.1016/j.eclinm.2024.102962,39720603,PMC11667630,,Wu 2025,2025,EClinicalMedicine,Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents
#13491,10.1093/cid/ciae649,39724318,PMC12302017,,Birabaharan 2024,2024,Clin Infect Dis,Atrial Fibrillation after RSV Vaccination Among Older Adults
#23468,10.1016/j.eclinm.2024.102995,39726669,PMC11669791,,Nguyen 2025,2025,EClinicalMedicine,Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform
#2768,10.1016/j.eclinm.2024.102986,39726670,PMC11669793,,OcanadeSentuary 2025,2025,eClinicalMedicine,Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France
#4195,10.1016/j.vaccine.2024.126662,39731809,,,Zhang 2025,2025,Vaccine,"Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
#3796,10.1016/j.jvacx.2024.100593,39734394,PMC11681879,,vanEwijk 2025,2025,Vaccine X,Innate immune response after BNT162b2 COVID-19 vaccination associates with reactogenicity
#2376,10.1111/cts.70095,39736101,PMC11684469,,Mao 2025,2025,Clin Transl Sci,"A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults"
#2165,10.1111/ene.70020,39739424,PMC11683473,,Lim 2025,2025,Eur J Neurol,The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study
#18637,10.35772/ghm.2024.01053,39741991,PMC11680453,,Shoji 2024,2024,Glob Health Med,Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan
#2316,10.1097/aog.0000000000005817,39746206,,,Madhi 2025,2025,Obstet Gynecol,Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
#3443,10.1097/aog.0000000000005816,39746212,,,Simões 2025,2025,Obstet Gynecol,"Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial"
#548,10.1016/j.msard.2024.106253,39756168,,,Briggs 2025,2025,Mult Scler Relat Disord,Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis
#1761,10.1016/j.jinf.2024.106405,39756693,,,Jorda 2025,2025,J Infect,"Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial"
#21056,10.1093/cid/ciae658,39761230,PMC12287938,,Chung 2025,2025,Clin Infect Dis,"Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
#16883,10.3390/biomedicines12122852,39767757,PMC11673082,,Mantovani 2024,2024,Biomedicines,Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
#8397,10.3390/vaccines12121409,39772070,PMC11680294,,Mansou 2024,2024,Vaccines,Reported Adverse Events Following SARS-CoV-2 Vaccinations in the Canadian Province of Alberta and Associated Risk Factors: A Retrospective Cohort Study
#633,10.1097/inf.0000000000004715,39773919,,,Carcione 2025,2025,Pediatr Infect Dis J,"ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024"
#23354,10.1093/braincomms/fcae448,39777257,PMC11703551,,Mukherjee 2025,2025,Brain Commun,Vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID
#2773,10.1002/pds.70082,39777941,PMC11706699,,Ogawa 2025,2025,Pharmacoepidemiol Drug Saf,Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study
#4093,10.1038/s41541-025-01065-5,39788985,PMC11718019,,Yaron 2025,2025,npj Vaccines,Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations
#3351,10.1111/1756-185x.70043,39791506,,,Shaharir 2025,2025,Int J Rheum Dis,Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study
#4595,10.3390/healthcare13010002,39791609,PMC11719995,,Anastácio 2024,2024,Healthcare (Basel),Relation Between COVID-19 Infection and Vaccine and Menstrual Cycle Changes of Portuguese Adolescents in Higher Education
#17154,10.7759/cureus.75889,39822416,PMC11737604,,Mohamed 2024,2024,Cureus,Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia
#2957,10.1097/inf.0000000000004672,39823640,,,Perramon-Malavez 2025,2025,Pediatr Infect Dis J,"Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain"
#177,10.1016/s1473-3099(24)00670-4,39824198,,,Alves 2025,2025,Lancet Infect Dis,Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
#1900,10.3346/jkms.2025.40.e10,39834222,PMC11745927,,Kim 2025,2025,J Korean Med Sci,Risk of Kawasaki Disease/Multisystem Inflammatory Syndrome Following COVID-19 Vaccination in Korean Children: A Self-Controlled Case Series Study
#1210,10.1080/21645515.2024.2436714,39836458,,,Figueroa 2025,2025,Hum Vaccin Immunother,Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
#244,10.1097/iae.0000000000004413,39841907,,,Arepalli 2025,2025,Retina,THE HETEROGENEOUS PRESENTATIONS OF DE NOVO AND RECURRENT OCULAR INFLAMMATION AFTER COVID-19 VACCINATION : A Multicenter Report and a Review of the Literature
#22825,10.1016/j.jacig.2024.100387,39844915,PMC11750530,,Lim 2025,2025,J Allergy Clin Immunol Glob,Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines
#338,10.1016/S1473-3099(24)00796-5,39848264,,,Bajema 2025,2025,LANCET INFECTIOUS DISEASES,"Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study"
#4272,10.3390/vaccines13010004,39852783,PMC11768588,,Zhu 2025,2025,Vaccines,Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative Case–Control Study
#21167,10.3390/vaccines13010042,39852821,PMC11769184,,Dammann 2025,2025,Vaccines (Basel),Influenza Immunization in Very-Low-Birth-Weight Infants: Epidemiology and Long-Term Outcomes
_#2063,10.1002/cpt.3565,39854110,,,Lee 2025,2025,Clin Pharmacol Ther,Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population-Based Cohort Study
#2742,10.1016/j.joca.2024.12.010,39855291,PMC11954666,,Nong 2025,2025,Osteoarthritis Cartilage,Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study
#314,10.1016/j.lana.2024.100984,39866362,PMC11764319,,Babalola 2025,2025,The Lancet Regional Health - Americas,SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study
#3665,10.1016/j.eclinm.2024.103016,39866854,PMC11764035,,Tapia-Calle 2025,2025,eClinicalMedicine,"Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial"
#337,10.1001/jamainternmed.2024.7452,39869355,PMC11773409,,Bajema 2025,2025,JAMA Intern Med,"Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus"
#428,10.1016/j.jinf.2025.106428,39874991,,,Bennett 2025,2025,J Infect,"Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial"
#1670,10.1016/j.vaccine.2025.126754,39879847,,,Ito 2025,2025,Vaccine,"Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan"
#20993,10.1210/clinem/dgaf064,39883558,,,Cheng 2025,2025,J Clin Endocrinol Metab,"Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network"
#3337,10.2807/1560-7917.Es.2025.30.4.2500059,39885824,,,Separovic 2025,2025,Euro Surveill,"Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25"
#7891,10.1016/j.jvacx.2024.100570,39886534,PMC11780392,,Lee 2024,2024,VACCINE: X,"Influenza vaccine effectiveness against influenza-associated hospitalizations in children, Hong Kong, November 2023 to June 2024"
#1336,10.1016/s2214-109x(24)00473-x,39890222,,,Gharpure 2025,2025,Lancet Glob Health,Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design
#13126,10.1136/bmjmed-2024-001074,39902239,PMC11789462,,Andersson 2024,2024,BMJ Med,"Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data"
#21702,10.1016/j.eclinm.2024.103054,39902315,PMC11788791,,Garrett 2025,2025,EClinicalMedicine,Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
#1647,10.7326/annals-24-01015,39903865,,,Ioannou 2025,2025,Ann Intern Med,Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation
#2751,10.2807/1560-7917.Es.2025.30.5.2400596,39916606,,,Núñez 2025,2025,Euro Surveill,"Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season"
#3484,10.1016/j.vaccine.2025.126847,39919447,,,Soens 2025,2025,Vaccine,A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults
#24941,10.1093/cid/ciaf061,39928572,,,Walsh 2025,2025,Clin Infect Dis,"Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons"
#1627,10.1038/s41598-025-88713-x,39939373,PMC11821952,,Hwang 2025,2025,Sci Rep,Global burden of vaccine-associated kidney injury using an international pharmacovigilance database
#1471,10.1016/j.vaccine.2025.126894,39970594,,,Hall 2025,2025,Vaccine,"COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021"
#10424,10.1016/j.lanepe.2024.101025,39974773,PMC11838104,,Suseeladevi 2024,2024,The Lancet Regional Health - Europe,"COVID-19 vaccination and birth outcomes of 186,990 women vaccinated before pregnancy: an England-wide cohort study"
#470,10.2459/jcm.0000000000001693,39976066,,,Birtolo 2025,2025,J Cardiovasc Med (Hagerstown),Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology
#2444,10.1016/j.jinf.2025.106447,39978439,,,Mazarakis 2025,2025,J Infect,"The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose"
#3168,10.2807/1560-7917.Es.2025.30.7.2500102,39980423,,,Rose 2025,2025,Euro Surveill,"Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
#3602,10.2807/1560-7917.Es.2025.30.7.2500084,39980425,,,Sun 2025,2025,Euro Surveill,"Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
#484,10.2807/1560-7917.Es.2025.30.7.2500074,39980426,,,Blanquart 2025,2025,Euro Surveill,"Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025"
#2314,10.1016/j.vaccine.2025.126892,39983541,,,Mackenzie 2025,2025,Vaccine,What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA)
#202,10.1016/j.vaccine.2025.126881,39987879,,,Andersen 2025,2025,Vaccine,Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states
#1606,10.1155/ijbc/8126974,39991115,PMC11846679,,Huang 2025,2025,International Journal of Breast Cancer,Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography
#4131,10.1001/jamanetworkopen.2024.59672,39992656,PMC11851240,,Yousaf 2025,2025,JAMA Netw Open,COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years
#3948,10.1080/21645515.2025.2468074,39993940,PMC11853548,,Wen 2025,2025,Hum Vaccin Immunother,Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3-8 years with or without previous influenza vaccination histories
#1001,10.1016/j.vaccine.2025.126869,39999538,,,Diya 2025,2025,Vaccine,A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
#1849,10.3390/vaccines13020103,40006650,PMC11860179,,Kern 2025,2025,Vaccines,Leukocyte Count in Solid Organ Transplant Recipients After SARS-CoV-2 mRNA Vaccination and Infection
#1359,10.3390/vaccines13020113,40006661,PMC11861871,,Göbel 2025,2025,Vaccines (Basel),Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used
#1737,10.3390/vaccines13020147,40006694,PMC11861186,,Jiménez-Corona 2025,2025,Vaccines,COVID-19 Vaccination Uptake and Effectiveness for Hospitalized Cases Among Healthcare Workers in Tertiary Hospital
#2695,10.3390/vaccines13020158,40006705,PMC11860858,,Neutel 2025,2025,Vaccines,Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
#3209,10.3390/vaccines13020161,40006708,PMC11861607,,Saavedra 2025,2025,Vaccines,"Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022"
#24345,10.3390/vaccines13020176,40006723,PMC11860193,,Shemer 2025,2025,Vaccines (Basel),COVID-19 Vaccination and Acute Anterior Uveitis-A Case Control Study
#4169,10.3390/vaccines13020189,40006735,PMC11861709,,Zawiasa-Bryszewska 2025,2025,Vaccines,Safety and Efficacy of Influenza Vaccination in Kidney Graft Recipients in Late Period After Kidney Transplantation
#2796,10.3390/vaccines13020192,40006738,PMC11860627,,Omole 2025,2025,Vaccines,"Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age"
#784,10.3390/vaccines13020197,40006743,PMC11861641,,Choi 2025,2025,Vaccines,Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023–2024 Season
#2182,10.15585/mmwr.mm7406a1,40014628,PMC11867580,,Link-Gelles 2025,2025,MMWR Morb Mortal Wkly Rep,"Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025"
#1181,10.15585/mmwr.mm7406a3,40014654,PMC11867584,,Fazal 2025,2025,MMWR Morb Mortal Wkly Rep,"Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons"
#1265,10.15585/mmwr.mm7406a2,40014791,PMC11867582,,Frutos 2025,2025,MMWR Morb Mortal Wkly Rep,"Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
#3014,10.1111/apm.70010,40017167,,,Pratt 2025,2025,APMIS,"Prevalence and Co-Detection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus: A Retrospective Analysis"
#2433,10.1111/ped.15892,40019392,,,Matsunashi 2025,2025,Pediatr Int,Rate of vertical transmission of coronavirus disease 2019 and effect of maternal vaccination: A prospective cohort study
#3135,10.1016/j.vaccine.2025.126946,40023131,,,Rigamonti 2025,2025,Vaccine,Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children
#9612,10.1016/j.vaccine.2025.126946,40023131,,,Rigamonti 2024,2024,Vaccine,Real-World Effectiveness of Live Attenuated vs. Inactivated Influenza Vaccines in Children
#2106,10.3389/fimmu.2025.1470609,40034704,PMC11872700,,Levy 2025,2025,Front Immunol,XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants
#21796,10.1016/j.lana.2025.101026,40040820,PMC11875141,,Gottlieb 2025,2025,Lancet Reg Health Am,"Differences in Long COVID severity by duration of illness, symptom evolution, and vaccination: a longitudinal cohort study from the INSPIRE group"
#11770,10.1007/s00431-025-06050-7,40044918,,,Marouk 2025,2025,Eur J Pediatr,Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study
#1202,10.3389/fmed.2025.1501921,40046918,PMC11879978,,Ferreira-da-Silva 2025,2025,Front Med (Lausanne),Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance
#3927,10.1016/j.jinf.2025.106461,40054670,,,Ward 2025,2025,J Infect,Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection Study
#19,10.1186/s12889-025-21765-w,40055620,PMC11889865,,AbdulRahim 2025,2025,BMC Public Health,Association of COVID-19 infection and COVID-19 vaccination with idiopathic sudden sensorineural hearing loss in Malaysia: a case-control study
#22655,10.1001/jama.2025.1225,40063039,PMC12277020,,Lauring 2025,2025,Jama,Genomic Characterization of RSV in the US by Vaccination Status
#24,10.1080/22221751.2025.2466699,40071892,PMC11980197,,AbouChakra 2025,2025,Emerg Microbes Infect,Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024
#506,10.1016/j.vaccine.2025.126907,40073670,PMC11975468,,Bolu 2025,2025,Vaccine,"Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021"
#2581,10.1016/j.lana.2025.101031,40083966,PMC11904515,,MoreiraPuga 2025,2025,The Lancet Regional Health - Americas,"Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil"
#25300,10.1093/eurjcn/zvaf033,40085436,,,Yoon 2025,2025,Eur J Cardiovasc Nurs,Health-related quality of life in adolescents with myocarditis and pericarditis after BNT162b2 COVID-19 vaccination: Korean national surveillance
#21760,10.1016/j.therap.2025.02.007,40090811,,,Gligorov 2025,2025,Therapie,Vaccines and the risk of Guillain-Barré syndrome: A French pharmacovigilance analysis
#22789,10.21203/rs.3.rs-6096098/v1,40092435,PMC11908350,,Li 2025,2025,Res Sq,Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent Vaccines
#23473,10.1016/j.lanwpc.2025.101506,40092586,PMC11910125,,Nguyen 2025,2025,Lancet Reg Health West Pac,Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia
#1894,10.3390/jcm14051767,40095916,PMC11900331,,Kim 2025,2025,Journal of Clinical Medicine,Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study
#183,10.1080/21645515.2025.2475616,40098448,,,AmaraldeAvilaMachado 2025,2025,Hum Vaccin Immunother,Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season
#22192,10.1002/bcp.70045,40099868,PMC12304821,,Jajou 2025,2025,Br J Clin Pharmacol,General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study
#1407,10.3238/arztebl.m2025.0032,40101263,,,Grieshaber 2025,2025,Dtsch Arztebl Int,The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study)
#23729,10.1016/j.jaad.2025.03.021,40107504,,,Pathak 2025,2025,J Am Acad Dermatol,Vitiligo development following COVID-19 vaccination: A retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System
#776,10.1093/ofid/ofaf115,40110421,PMC11919815,,Choi 2025,2025,Open Forum Infectious Diseases,"Rates of Hospitalization and Death due to COVID-19 in US Veterans with SARS-CoV-2 Infection in the XBB-, JN.1-, and KP-Predominant Eras"
#4155,10.3389/fpubh.2025.1420291,40115337,PMC11922928,,Zaidi 2025,2025,Front Public Health,COVID-19 vaccines side effects among the general population during the pandemic: a cross-sectional study
#1415,10.1111/ene.16510,40115993,PMC11926444,,Grisanti 2025,2025,Eur J Neurol,Neurological long COVID in the outpatient clinic: Is it so long?
#2757,10.1089/cap.2024.0129,40127994,,,O'Dor 2025,2025,J Child Adolesc Psychopharmacol,Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination
#768,10.3346/jkms.2025.40.e101,40132537,PMC11932827,,Cho 2025,2025,J Korean Med Sci,"Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database"
#3137,10.1111/apa.70066,40135713,,,Rius-Peris 2025,2025,Acta Paediatr,Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns
#21752,10.3390/microorganisms13030469,40142362,PMC11945264,,Giovanetti 2025,2025,Microorganisms,Epidemiological Transitions in Influenza Dynamics in the United States: Insights from Recent Pandemic Challenges
#20901,10.14744/AnatolJCardiol.2025.5105,40151843,PMC12231392,,Çetinkaya 2025,2025,Anatol J Cardiol,"COVID-19 Infection, Vaccination, and Severe Coronary Artery Disease in Türkiye: A Retrospective Analysis"
#46,10.1016/j.jaci.2025.03.015,40154575,,,Adelglass 2025,2025,J Allergy Clin Immunol,Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses
#3691,10.1177/09612033251331244,40156281,,,Thepveera 2025,2025,Lupus,Disease exacerbation and COVID-19 following mRNA COVID-19 vaccination in adolescents with Systemic Lupus Erythematosus
#1107,10.2807/1560-7917.Es.2025.30.12.2500174,40156348,,,Emborg 2025,2025,Euro Surveill,"Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025"
#1527,10.1016/j.ajt.2025.03.025,40169094,,,Havlin 2025,2025,Am J Transplant,Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees
#290,10.1371/journal.pone.0311459,40173404,PMC11964452,,Awasthi 2025,2025,PLoS One,Emergence to dominance: Estimating time to dominance of SARS-CoV-2 variants using nonlinear statistical models
#1798,10.1080/21645515.2025.2484088,40174609,PMC11970786,,Kandinov 2025,2025,Hum Vaccin Immunother,An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers
#11951,10.15585/mmwr.mm7411a1,40179043,PMC11970723,,Jobe 2025,2025,MMWR Morb Mortal Wkly Rep,"Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024"
#178,10.1016/j.vaccine.2025.127046,40184816,,,Alves 2025,2025,Vaccine,"Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study"
#2925,10.1016/j.vaccine.2025.127010,40184817,,,Payne 2025,2025,Vaccine,"Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged ≥18 years with end stage kidney disease - United States, September 2023-April 2024"
#2815,10.1016/j.jocn.2025.111223,40184822,,,Ota 2025,2025,J Clin Neurosci,Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination
_#116,10.1136/bmjopen-2024-087850,40187782,PMC11973799,,Alami 2025,2025,BMJ Open,Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System
#1735,10.1080/22221751.2025.2490531,40192342,PMC12164376,,Jiang 2025,2025,Emerg Microbes Infect,Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season
#6708,10.5001/omj.2024.107,40196803,PMC11973885,,Hammam 2024,2024,Oman Medical Journal,Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt
#22737,10.1093/infdis/jiaf185,40198276,,,Lewis 2025,2025,J Infect Dis,"Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
#2229,10.1016/j.vaccine.2025.127069,40203591,,,Lloyd 2025,2025,Vaccine,Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older
#1789,10.1016/j.artd.2025.101673,40231045,PMC11995801,,Kamalapathy 2025,2025,Arthroplasty Today,Vaccination Status is Not Associated With Adverse Postoperative Outcomes Following Total Joint Arthroplasty in Patients With a Preoperative COVID-19 Diagnosis
#24180,10.1007/s40264-025-01547-4,40238055,PMC12259799,,Sankar 2025,2025,Drug Saf,Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System
#1665,10.1016/s2213-2600(25)00048-7,40245915,,,Ison 2025,2025,Lancet Respir Med,"Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial"
#1712,10.1038/s41598-025-98106-9,40247100,PMC12006434,,Jeong 2025,2025,Sci Rep,Global and regional estimates of vaccine-associated herpes zoster and their related vaccines from 1969 to 2023
#23161,10.1007/s00467-025-06778-2,40261402,,,Mazza 2025,2025,Pediatr Nephrol,Association of COVID-19 vaccination with relapsed nephrotic syndrome and new onset nephrotic syndrome in children
#3689,10.3390/medsci13020038,40265385,PMC12015835,,Thanh 2025,2025,Med Sci (Basel),Safety of and Adverse Reactions to the COVID-19 Vaccine Among Pregnant and Breastfeeding Women
#24912,10.3390/vaccines13030273,40266144,PMC11946322,,Vita 2025,2025,Vaccines (Basel),COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
#3688,10.3390/vaccines13030289,40266198,PMC11946013,,Thanborisutkul 2025,2025,Vaccines,Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines
#156,10.3390/vaccines13030328,40266222,PMC11946143,,Almeida 2025,2025,Vaccines,Immunogenicity and Safety of the Bivalent Respiratory Syncytial Virus Prefusion F Subunit Vaccine in Immunocompromised or Renally Impaired Adults
#40,10.3390/vaccines13030309,40266236,PMC11946095,,AcutiMartellucci 2025,2025,Vaccines,"The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study"
#24824,10.7759/cureus.81085,40271323,PMC12017381,,Umezawa 2025,2025,Cureus,A Series of Glomerular Diseases That Developed After COVID-19 Vaccination
#706,10.1016/j.eclinm.2025.103171,40276143,PMC12018050,,Chen 2025,2025,eClinicalMedicine,Interaction between influenza vaccine and statins affecting the risk of rhabdomyolysis in Taiwan: a nationwide case-centred analysis
#1208,10.3389/fimmu.2025.1501275,40276503,PMC12018429,,Fierro 2025,2025,Front Immunol,Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study
#1246,10.1038/s41598-025-98313-4,40289148,PMC12034749,,Fraenza 2025,2025,Sci Rep,Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination
#489,10.5694/mja2.52655,40293046,PMC12167606,,Bloomfield 2025,2025,Med J Aust,"Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis"
#3989,10.1136/rmdopen-2024-005138,40295118,PMC12039019,,Woo 2025,2025,RMD Open,Risk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study
#233,10.1038/s41467-025-59344-7,40301395,PMC12041242,,Appaneal 2025,2025,Nat Commun,Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System
#367,10.1016/j.neurol.2025.04.007,40307085,,,Barnay 2025,2025,Rev Neurol (Paris),The safety of COVID-19 vaccines in a large French series of patients with neuromuscular conditions and the impacts of vaccination on their daily lives
#3394,10.1097/aog.0000000000005904,40311142,,,Sheth 2025,2025,Obstet Gynecol,Coronavirus Disease 2019 (COVID-19) Vaccination and Spontaneous Abortion
#3643,10.1016/j.resinv.2025.04.016,40319702,,,Tamura 2025,2025,Respir Investig,"Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults"
#1739,10.1016/j.ajog.2025.04.067,40324666,PMC12353535,,JinHsieh 2025,2025,Am J Obstet Gynecol,Investigation of Maternal Outcomes Following Respiratory Syncytial Virus Vaccination in the Third Trimester: Insights from a Real-World U.S. Electronic Health Records Database
#2231,10.1002/pds.70151,40328431,,,Lloyd 2025,2025,Pharmacoepidemiol Drug Saf,Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States
#1117,10.1111/irv.70115,40328669,PMC12055342,,Erdwiens 2025,2025,Influenza Other Respir Viruses,Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance
#1896,10.3346/jkms.2025.40.e63,40329789,PMC12056060,,Kim 2025,2025,J Korean Med Sci,Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea
#3188,10.1001/jama.2025.5646,40332892,PMC12060023,,RudmanSpergel 2025,2025,Jama,Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial
#1199,10.3390/vaccines13040396,40333295,PMC12031101,,Ferraioli 2025,2025,Vaccines,Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies
#2692,10.3390/vaccines13040392,40333305,PMC12031221,,Nelli 2025,2025,Vaccines,Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study
#2105,10.3390/vaccines13040398,40333311,PMC12031295,,Levy 2025,2025,Vaccines,Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains
#2916,10.15585/mmwr.mm7416a1,40338822,PMC12061057,,Patton 2025,2025,MMWR Morb Mortal Wkly Rep,"Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025"
#23773,10.1016/s1473-3099(25)00156-2,40339585,,,PérezMarc 2025,2025,Lancet Infect Dis,"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study"
#1934,10.4178/epih.e2025024,40340265,,,Ko 2025,2025,Epidemiol Health,Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study
#1266,10.1001/jamanetworkopen.2025.8322,40343698,PMC12065041,,Fry 2025,2025,JAMA Netw Open,Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older
#3178,10.1016/j.vaccine.2025.127217,40344810,,,Rouleau 2025,2025,Vaccine,"New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada"
#24853,10.1038/s43856-025-00891-x,40348868,PMC12065847,,VanRampelbergh 2025,2025,Commun Med (Lond),Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines
#22899,10.1016/j.cmi.2025.05.002,40349967,,,Livne 2025,2025,Clin Microbiol Infect,Hybrid and vaccination immunity against severe COVID-19 in the post-pandemic era-a retrospective cohort study
#24573,10.3389/fphar.2025.1561410,40356957,PMC12066665,,Subaiea 2025,2025,Front Pharmacol,Charting the COVID-19 vaccination journey in Saudi Arabia: Insights into post-vaccination adverse effects and immunization dynamics
#25499,10.1093/infdis/jiaf248,40359401,PMC12353657,,Zhu 2025,2025,J Infect Dis,"Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season"
#36,10.1093/gerona/glaf108,40371440,PMC12202091,,Abul 2025,2025,J Gerontol A Biol Sci Med Sci,Incidence of Long COVID Diagnoses in 3.6 Million U.S. Medicare Beneficiaries With COVID-19
#3018,10.1016/j.jns.2025.123536,40373476,,,Primicerio 2025,2025,J Neurol Sci,Small fiber neuropathy following COVID-19 vaccination: A case series
#24752,10.1016/j.jpeds.2025.114642,40373954,,,Top 2025,2025,J Pediatr,Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study
#2631,10.1016/s2352-4642(25)00102-6,40379431,,,Munro 2025,2025,Lancet Child Adolesc Health,"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial"
#3999,10.1371/journal.pone.0310474,40392910,PMC12091759,,Wu 2025,2025,PLoS One,Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis
#2033,10.1111/irv.70120,40395132,PMC12093050,,LanieceDelaunay 2025,2025,Influenza Other Respir Viruses,"COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network"
#3372,10.1002/bdr2.2474,40395208,PMC12093198,,Sharma 2025,2025,Birth Defects Res,"COVID-19 Vaccination During Pregnancy and Birth Defects: Results From the CDC COVID-19 Vaccine Pregnancy Registry, United States 2021-2022"
#2715,10.1016/j.vaccine.2025.127275,40398327,,,Nham 2025,2025,Vaccine,Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months
#1221,10.1016/j.vaccine.2025.127254,40398329,,,Fitzpatrick 2025,2025,Vaccine,Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network
#21593,10.1016/s1473-3099(25)00153-7,40412421,,,Folegatti 2025,2025,Lancet Infect Dis,"Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study"
#2339,10.1016/j.vaccine.2025.127297,40418866,,,Malange 2025,2025,Vaccine,"Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019"
#2076,10.1016/j.vaccine.2025.127300,40424706,,,Lee 2025,2025,Vaccine,"Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada"
#2684,10.1038/s41598-025-03428-3,40425703,PMC12116907,,Nazar 2025,2025,Sci Rep,Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database
#2252,10.3390/ph18050636,40430457,PMC12114770,,LópezdeLasHuertas 2025,2025,Pharmaceuticals (Basel),Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance
#1605,10.3390/vaccines13050467,40432079,PMC12116156,,Huang 2025,2025,Vaccines,"The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial"
#111,10.1590/1519-6984.289927,40435071,,,Al-Muzafar 2025,2025,Braz J Biol,"Self-reported post-vaccination side effects of each of the three rounds of COVID-19 vaccinations: the case in the Eastern Province, Saudi Arabia"
#1051,10.1177/14034948251333901,40439194,,,Dudukina 2025,2025,Scand J Public Health,Associations between mRNA COVID-19 vaccination and urticaria: a nationwide registry-based cohort study in Denmark
#21721,10.1097/inf.0000000000004878,40440704,,,Gentile 2025,2025,Pediatr Infect Dis J,Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study
#20369,10.1097/inf.0000000000004866,40440707,,,Andersen 2025,2025,Pediatr Infect Dis J,"Clinical Outcomes in Children <5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States"
#2677,10.1016/j.vaccine.2025.127291,40440921,,,Nasreen 2025,2025,Vaccine,Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study
#3019,10.3389/ti.2025.14187,40454297,PMC12124284,,Prins 2025,2025,Transpl Int,A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Influenza Among Immunocompromised Adults With a Solid Organ Transplant
#2066,10.1002/jmv.70408,40454841,,,Lee 2025,2025,J Med Virol,Global and Regional Burden of Vaccine-Associated Transverse Myelitis and Potentially Associated With Vaccines From 1967 to 2023: An Analysis of the International Pharmacovigilance Data
#22585,,40455969,PMC12186818,,Kwaah 2025,2025,MSMR,"Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season"
#22376,10.1016/j.jiac.2025.102728,40456446,,,Kawai 2025,2025,J Infect Chemother,Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season
#630,10.1371/journal.pone.0325269,40460407,PMC12133164,,Carazo 2025,2025,PLoS One,"Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up"
#23153,10.1093/cid/ciaf292,40464662,,,Mayer 2025,2025,Clin Infect Dis,"Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years"
#3980,10.1002/bdr2.2490,40476384,PMC12142568,,Woestenberg 2025,2025,Birth Defects Res,Comparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in the Netherlands
#22221,10.1007/s00228-025-03854-2,40478262,,,Jeong 2025,2025,Eur J Clin Pharmacol,"Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database"
#20412,10.1016/j.vaccine.2025.127337,40479930,,,Arcolaci 2025,2025,Vaccine,A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines
#13033,10.4103/heartviews.heartviews_62_24,40488147,PMC12139649,,Ali 2024,2024,Heart Views,A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination
#119,10.1016/j.rcsop.2025.100614,40502459,PMC12152863,,Albahari 2025,2025,Exploratory Research in Clinical and Social Pharmacy,Impact of mRNA COVID-19 vaccination on hematological parameters in patients maintained on clozapine: A retrospective study from Qatar
#1921,10.2807/1560-7917.Es.2025.30.23.2500011,40511473,,,Kissling 2025,2025,Euro Surveill,"Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
#3727,10.1016/s1473-3099(25)00233-6,40513593,,,Torres 2025,2025,Lancet Infect Dis,Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study
#20449,10.2147/ijgm.S520084,40547349,,,Asiri 2025,2025,Int J Gen Med,Adverse Cutaneous Reactions Following COVID-19 Vaccination Among Patients with Pre-Existing Urticaria: A Cross-Sectional Study at a Tertiary Care Center in Saudi Arabia
#24705,10.1016/j.ijid.2025.107964,40550307,,,Teodoro 2025,2025,Int J Infect Dis,Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults
#1948,10.1080/21645515.2025.2518646,40555671,,,Konishi 2025,2025,Hum Vaccin Immunother,Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions
#2183,10.1001/jamanetworkopen.2025.17402,40560584,PMC12199055,,Link-Gelles 2025,2025,JAMA Netw Open,Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults
#416,10.1016/j.vaccine.2025.127392,40561570,,,Beller 2025,2025,Vaccine,Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial
#23715,10.1016/j.virol.2025.110613,40561867,,,Pasquale 2025,2025,Virology,"Safety of SARS-CoV-2 XBB.1.5 and seasonal influenza vaccines co-administration: data from a perspective observational active surveillance study. Puglia (Italy), season 2023/2024"
#21482,10.3390/cancers17121948,40563598,PMC12191419,,Fabbri 2025,2025,Cancers (Basel),Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study
#23868,10.3390/children12060678,40564636,PMC12190996,,Prasertsakul 2025,2025,Children (Basel),Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study
#2043,10.1093/ofid/ofaf334,40567998,,,LaVerriere 2025,2025,Open Forum Infectious Diseases,"Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024"
#1130,10.3390/vaccines13060623,40573954,PMC12197746,,Estrella-Porter 2025,2025,Vaccines (Basel),Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign
#24371,10.1016/j.vaccine.2025.127429,40578174,,,Shinjoh 2025,2025,Vaccine,"Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine"
#39863,10.1007/s40121-025-01185-4,40591130,PMC12339817,,Diya 2025,2025,Infect Dis Ther,Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
#39405,10.1038/s41598-025-04049-6,40592905,PMC12215190,,Jeong 2025,2025,Sci Rep,Global estimates of vaccine-associated narcolepsy from 1967 to 2023
#39866,10.1186/s12879-025-11254-1,40624462,PMC12232647,,Prabhu 2025,2025,BMC Infect Dis,"Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia"
#38986,10.1038/s41598-025-10633-7,40634642,PMC12241609,,Mutter 2025,2025,Sci Rep,Association between influenza vaccine effectiveness and chronic diseases among older adults with dementia
#22678,10.4178/epih.e2025034,40635461,,,Lee 2025,2025,Epidemiol Health,Identifying adverse reactions following COVID-19 vaccination from data collected through active surveillance: a text mining approach
#39867,10.1080/21645515.2025.2525603,40641250,PMC12258169,,Li 2025,2025,Hum Vaccin Immunother,The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024
#21621,10.1371/journal.pone.0326231,40644466,PMC12250466,,Frankenthal 2025,2025,PLoS One,Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients
#39217,10.1016/j.jamda.2025.105760,40651496,,,Popham 2025,2025,J Am Med Dir Assoc,Disproportionate Impact of Respiratory Syncytial Virus (RSV) Among Older Adults in Long-Term Care Settings
#39349,10.1080/09286586.2025.2522724,40658089,,,Sumer 2025,2025,Ophthalmic Epidemiol,Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium
#39260,10.1016/j.vaccine.2025.127483,40660660,PMC12305427,,Reeves 2025,2025,Vaccine,Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age
#38977,10.1002/ppul.71059,40662491,PMC12261432,,Guerrero-Del-Cueto 2025,2025,Pediatr Pulmonol,Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital
#39341,10.1038/s41467-025-61613-4,40664645,PMC12264068,,Pan 2025,2025,Nat Commun,Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study
#37186,10.3389/fpubh.2025.1520821,40672927,PMC12263602,,Tursinov 2025,2025,Front Public Health,"COVID-19 vaccination pharmacovigilance in Khojaly district, Uzbekistan: an epidemiological evaluation"
#32258,10.1016/j.pmedr.2025.103150,40678810,PMC12269873,,Li 2025,2025,Prev Med Rep,"Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024"
#39029,10.1016/s2352-4642(25)00155-5,40690922,,,Williams 2025,2025,Lancet Child Adolesc Health,"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study"
#3965,10.1016/S2352-4642(25)00155-5,40690922,,,Williams 2025,2025,Lancet Child Adolesc Health,"Bivalent Prefusion F Vaccination in Pregnancy and Respiratory Syncytial Virus Hospitalisation in Infants: Results of a Prospective, Multi-Centre, Test-Negative Study"
#39722,10.1016/j.vaccine.2025.127514,40714528,,,Omole 2025,2025,Vaccine,"A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older"
#39963,10.1016/j.vaccine.2025.127548,40716143,,,Xu 2025,2025,Vaccine,Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study
#39868,10.1001/jamanetworkopen.2025.23557,40720126,PMC12305385,,Andersson 2025,2025,JAMA Netw Open,Safety of JN.1-Updated mRNA COVID-19 Vaccines
#39262,10.1093/jpids/piaf069,40736196,PMC12392406,,Nguyen 2025,2025,J Pediatric Infect Dis Soc,"Effectiveness of cell culture-based influenza vaccine, 2023-2024"
#39547,10.1001/jama.2025.11534,40736730,PMC12311823,,Silverman 2025,2025,Jama,Influenza-Associated Acute Necrotizing Encephalopathy in US Children
#39961,10.1007/s11739-025-04054-7,40739393,,,Donadini 2025,2025,Intern Emerg Med,Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry
#2068,10.1093/pch/pxae101,40756534,PMC12316524,,Lee 2025,2025,PAEDIATRICS & CHILD HEALTH,Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: A population-based study
#6030,10.1016/j.cegh.2024.101689,,,,ElHilali 2024,2024,Clinical Epidemiology and Global Health,Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic
#77,10.1016/j.cegh.2025.101975,,,,AhmedAlQahtani 2025,2025,Clinical Epidemiology and Global Health,"Short and long-term side effects of eligible COVID-19 vaccines in Saudi Arabia, Southern Region, 2023"
#3434,10.1016/j.eimc.2025.03.006,40467410,,,Silva-Afonso 2025,2025,ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA,Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department
#4459,10.1016/j.imu.2024.101564,,,,Al-Rousan 2024,2024,Informatics in Medicine Unlocked,"Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis"
#2845,10.1016/j.jvacx.2025.100645,,,,Pakanen 2025,2025,VACCINE: X,COVID-19 vaccination as a rare potential etiology for cause of death after medicolegal autopsy. A Finnish nationwide study
#1013,10.1016/j.jvacx.2025.100647,,,,Domnich 2025,2025,VACCINE: X,Enhanced safety surveillance of the adjuvanted respiratory syncytial virus vaccine among Italian older adults
#2956,10.1016/j.lanepe.2025.101334,40950943,PMC12426819,,Perramon-Malavez 2025,2025,The Lancet Regional Health - Europe,Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis
#4532,10.1016/j.vacun.2024.04.004,,,,Almodóvar-Fernández 2024,2024,Vacunas,SARS-CoV-2 vaccination effect over coagulation in 60s patients treated with acenocumarol
#8551,10.15789/2220-7619-SAE-17550,,,https://iimmun.ru/iimm/article/view/17550,Meidani 2024,2024,Russian Journal of Infection and Immunity,SAFETY AND EFFECTIVENESS OF SINGLE- VERSUS DOUBLE-DOSE OF SEASONAL INFLUENZA VACCINE IN KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED CLINICAL TRIAL
#8692,10.17966/JMI.2024.29.3.117,,,,Moon 2024,2024,Journal of Mycology and Infection,"Cutaneous Manifestations of COVID-19 Vaccination and COVID-19 Infection: a Questionnaire-based, Multi-center Study in Korea"
#38920,10.23958/ijirms/vol09-i11/1982,,,,Rogers 2024,2024,International Journal of Innovative Research in Medical Science,COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes
#8197,10.24875/CIRUE.M23000425,,,,López-Contreras 2023,2023,Cirugia y Cirujanos,Incidence and factors associated with early and late adverse reactions after the first dose of Pfizer-BioNTech vaccine among healthcare workers
#4110,10.4103/apjtm.apjtm_253_24,,,,Yildirim 2025,2025,Asian Pacific Journal of Tropical Medicine,COVID-19 vaccination in patients on biologic or targeted-synthetic disease modifying anti-rheumatic drug therapy: A multi center real-world data
#11374,10.4274/BMB.galenos.2024.2024-03-030,,,,YumruÇeliksoy 2024,2024,Bagcilar Medical Bulletin,Impact of Pfizer-BioNTech COVID-19 Vaccination on the Menstrual Cycle
#9094,10.5114/pja.2024.138498,,,,Özdemir 2024,2024,Alergologia Polska - Polish Journal of Allergology,The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience
#4744,10.52142/omujecm.41.2.13,,,,Aydin 2024,2024,Journal of Experimental and Clinical Medicine (Turkey),"Effect of COVID-19 mRNA vaccine on serum AMH, TSH, FSH and LH concentrations"
#6043,10.53555/6vk1cf91,,,,Elemuwa 2024,2024,Journal of Population Therapeutics and Clinical Pharmacology,TRENDS OF COVID-19 VACCINE ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI): A ONE-YEAR RETROSPECTIVE REVIEW USING THE PASSIVE SURVEILLANCE DATA IN THE NIGERIAN NATIONAL DATABASE (VIGIFLOW)
#1175,10.53555/thn9g804,,,,Fatima 2025,2025,Journal of Population Therapeutics and Clinical Pharmacology,MENSTRUAL IRREGULARITIES IN WOMEN AFTER COVID-19 INFECTION AND VACCINATION: A COMMUNITY BASED STUDY AMONG DUBAI HOSPITAL FEMALE STAFF AND WOMEN ATTENDING GYNECOLOGY CLINIC AND EMERGENCY
#4320,,,,https://scielo.sld.cu/pdf/vac/v33/1025-0298-vac-33-e073324.pdf,Abdurakhmanov 2024,2024,VacciMonitor,Effect of inactivated and mRNA COVID-19 vaccines on thrombocytopenia in immune thrombocytopenia patients
#7061,,,,https://www.rmj.org.pk/fulltext/27-1689839434.pdf?1758757809,Imran 2024,2024,RAWAL MEDICAL JOURNAL,Adverse effects following Covid 19 vaccination among students of a Private Medical College